David Regan on Sona Nanotech's agreement with Siva Therapeutics to develop cancer treating therapies
Channel: InvestorCoffee
Date: 2023-01-27

In this InvestorIntel interview, Sona Nanotech Inc.’s (CSE: SONA | OTCQB: SNANF) CEO David Regan provides Tracy Weslosky with an update on Sona’s commercial agreement with Siva Therapeutics to develop therapies for treating cancer. As a strategic supplier of biocompatible gold nanorods to Siva, David discusses why Sona’s minimally invasive gold nanorods are the ideal material for use with Siva’s cancer tumor therapy system.

David says that the first targeted application will be for colorectal cancer which is the “second most mortal in the world.” David also talks about attracting world-class talent to Sona Nanotech’s board, including Neil Fraser, past-president of Medtronic Canada, and Walter Strapps, CEO and co-founder of Carver Biosciences Inc. They join Sona Nanotech director Mark Lievonen, former President of Sanofi Pasteur Limited.

About Sona Nanotech Inc.

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

Disclaimer: Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

#SonaNanotech #CancerTherapy #SivaTherapeutics